MCID: SLV003
MIFTS: 51

Salivary Gland Disease

Categories: Endocrine diseases, Immune diseases, Oral diseases

Aliases & Classifications for Salivary Gland Disease

MalaCards integrated aliases for Salivary Gland Disease:

Name: Salivary Gland Disease 12 55 15 17
Salivary Gland Disorders 77 44
Salivary Gland Diseases 56 74
Non-Neoplastic Salivary Gland Disorder 74
Non-Neoplastic Salivary Gland Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10854
ICD9CM 36 527.8

Summaries for Salivary Gland Disease

NINDS : 55 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Salivary Gland Disease, also known as salivary gland disorders, is related to igg4-related disease and anus basaloid carcinoma, and has symptoms including snoring, halitosis and oral manifestations. An important gene associated with Salivary Gland Disease is MAML2 (Mastermind Like Transcriptional Coactivator 2), and among its related pathways/superpathways are Circadian rythm related genes and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Pilocarpine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, eye and lymph node, and related phenotypes are no effect and growth/size/body region

MedlinePlus : 44 Your salivary glands are in your mouth. You have three pairs of major salivary glands and hundreds of small (minor) glands. They make saliva (spit) and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Problems with salivary glands can cause them to become irritated and swollen. You may have symptoms such as A bad taste in your mouth Difficulty opening your mouth Dry mouth Pain in your face or mouth Swelling of your face or neck Causes of salivary gland problems include infections, obstruction, or cancer. Problems can also be due to other disorders, such as mumps or Sjogren's syndrome.

Wikipedia : 77 Salivary gland diseases (SGD) are multiple and varied in... more...

Related Diseases for Salivary Gland Disease

Diseases related to Salivary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 igg4-related disease 11.1
2 anus basaloid carcinoma 10.4 CYLD KRT7
3 lacrimal gland mucoepidermoid carcinoma 10.4 CRTC1 MAML2
4 middle ear adenoma 10.4 ISL1 KRT7
5 breast mucoepidermoid carcinoma 10.4 CRTC1 MAML2
6 cutaneous adenocystic carcinoma 10.4 KRT7 NFIB
7 apocrine sweat gland neoplasm 10.4 CYLD KRT7
8 adult mesoblastic nephroma 10.4 ETV6 NTRK3
9 clear cell hidradenoma 10.4 CRTC1 MAML2
10 malignant spiradenoma 10.4 KRT7 TP53
11 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
12 vulvar intraepithelial neoplasia 10.4 KRT7 TP53
13 lacrimal system cancer 10.4 MAML2 NFIB NTRK3
14 vulval paget's disease 10.3 ERBB2 KRT7
15 cellular congenital mesoblastic nephroma 10.3 ETV6 NTRK3
16 lacrimal gland carcinoma 10.3 MAML2 NFIB
17 non-proliferative fibrocystic change of the breast 10.3 ERBB2 TP53
18 cutaneous mucoepidermoid carcinoma 10.3 CRTC1 KRT7 MAML2
19 spiradenoma 10.3 CYLD KRT7 TP53
20 pleomorphic adenoma carcinoma 10.3 ERBB2 MAML2 TP53
21 cervical adenosquamous carcinoma 10.3 CRTC1 KRT7 MAML2
22 bladder carcinoma in situ 10.3 KRT7 TP53
23 uterine corpus serous adenocarcinoma 10.3 ERBB2 TP53
24 pediatric fibrosarcoma 10.3 ETV6 NTRK3
25 herpangina 10.3 AMHR2 DPT MFSD6
26 vulvar disease 10.3 KRT7 TP53
27 acinar cell carcinoma 10.3 ETV6 KRT7 TP53
28 breast squamous cell carcinoma 10.3 ERBB2 TP53
29 mixed cell type cancer 10.3 ERBB2 KRT7 TP53
30 granulosa cell tumor of the ovary 10.3 ERBB2 KRT7 TP53
31 hidradenocarcinoma 10.3 ERBB2 KRT7 TP53
32 papillary adenocarcinoma 10.3 ERBB2 KRT7 TP53
33 papillary serous adenocarcinoma 10.3 KRT7 TP53
34 ovary adenocarcinoma 10.3 ERBB2 KRT7 TP53
35 ovarian cancer 1 10.3 ERBB2 KRT7 TP53
36 malignant ovarian surface epithelial-stromal neoplasm 10.3 ERBB2 KRT7 TP53
37 ovary epithelial cancer 10.2 ERBB2 KRT7 TP53
38 cervical adenocarcinoma 10.2 ERBB2 KRT7 TP53
39 sweat gland cancer 10.2 ERBB2 KRT7 TP53
40 cystadenocarcinoma 10.2 ERBB2 KRT7 TP53
41 malignant mesenchymoma 10.2 ETV6 NTRK3 TP53
42 carcinosarcoma 10.2 ERBB2 KRT7 TP53
43 endometrial adenocarcinoma 10.2 ERBB2 KRT7 TP53
44 breast adenoid cystic carcinoma 10.2 ERBB2 NFIB
45 renal cell carcinoma, papillary, 1 10.2 ERBB2 KRT7 TP53
46 differentiated thyroid carcinoma 10.2 ETV6 NTRK3 TP53
47 gastrointestinal system cancer 10.2 ERBB2 KRT7 TP53
48 uterine body mixed cancer 10.2 ERBB2 TP53
49 transitional cell carcinoma 10.2 ERBB2 KRT7 TP53
50 nasal cavity adenocarcinoma 10.2 KRT7 TP53

Graphical network of the top 20 diseases related to Salivary Gland Disease:



Diseases related to Salivary Gland Disease

Symptoms & Phenotypes for Salivary Gland Disease

UMLS symptoms related to Salivary Gland Disease:


snoring, halitosis, oral manifestations

GenomeRNAi Phenotypes related to Salivary Gland Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ALKBH1 ALKBH3 AMHR2 CPSF4 CRTC1 CRTC3

MGI Mouse Phenotypes related to Salivary Gland Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 ALKBH1 AMHR2 CRTC1 CRTC3 CYLD DPT
2 homeostasis/metabolism MP:0005376 10.18 ALKBH3 AMHR2 CRTC1 CRTC3 CYLD ERBB2
3 endocrine/exocrine gland MP:0005379 10.17 ALKBH1 AMHR2 CRTC1 CYLD ERBB2 ETV6
4 digestive/alimentary MP:0005381 10 CYLD ERBB2 ETV6 ISL1 NFIB SGTA
5 mortality/aging MP:0010768 9.93 ALKBH1 ALKBH3 AMHR2 CRTC3 CYLD ERBB2
6 integument MP:0010771 9.92 AMHR2 CYLD DPT ERBB2 ETV6 ISL1
7 limbs/digits/tail MP:0005371 9.8 ALKBH1 CRTC3 CYLD ERBB2 ISL1 MC3R
8 neoplasm MP:0002006 9.43 AMHR2 CYLD ERBB2 ETV6 ISL1 TP53
9 reproductive system MP:0005389 9.28 ALKBH1 AMHR2 CRTC1 ERBB2 ISL1 NTRK3

Drugs & Therapeutics for Salivary Gland Disease

Drugs for Salivary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pilocarpine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
2
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
5
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
6
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
7
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 9004-61-9 53477741
8 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
9
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
10
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 6473866 445643 439492
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
13
Cevimeline Approved Phase 4,Not Applicable 107233-08-9 25137844 83898
14
Oxybutynin Approved, Investigational Phase 4,Phase 2 5633-20-5 4634
15
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
16
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
17
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
18
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
19
Betaine Approved, Nutraceutical Phase 4,Not Applicable 107-43-7 247
20
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
21 Gallopamil Investigational Phase 4 16662-47-8
22 Rebamipide Investigational Phase 4,Phase 2,Not Applicable 90098-04-7
23 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Muscarinic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
26 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Calcium, Dietary Phase 4,Not Applicable
29 Antineoplastic Agents, Hormonal Phase 4,Phase 2
30 glucocorticoids Phase 4,Phase 2
31 Hormones Phase 4,Phase 2,Not Applicable
32 Hormone Antagonists Phase 4,Phase 2,Not Applicable
33 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
36 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
40 Cyclosporins Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Anti-Ulcer Agents Phase 4,Phase 2,Not Applicable
43 Antacids Phase 4,Phase 2,Not Applicable
44 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 DHEA (Dehydroepiandrosterone) Phase 4,Phase 2
49 Antioxidants Phase 4,Phase 2,Not Applicable
50 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 439)
# Name Status NCT ID Phase Drugs
1 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
2 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
5 Effects of Mucoprotective Product on Xerostomia Completed NCT01316393 Phase 4
6 Effect of Korean Red Ginseng (KRG) on Dry Mouth Completed NCT00911768 Phase 4
7 Evaluation of an Electro-stimulator for the Treatment of Xerostomia Completed NCT00509808 Phase 4
8 Comparison Between Rebamipide 2% Versus Autologous Serum Completed NCT03608761 Phase 4 Rebamipide
9 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
10 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
11 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
12 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
13 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
14 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
15 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
16 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
17 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
18 A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment Completed NCT00438048 Phase 4 Artificial Saliva
19 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
20 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
21 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
22 Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome Recruiting NCT03711214 Phase 4
23 Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Recruiting NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
24 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
25 Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use Withdrawn NCT02522936 Phase 4 Biotene oral spray
26 BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent Unknown status NCT02068846 Phase 3 Ciprofloxacin;Placebo
27 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
28 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Unknown status NCT02257957 Phase 3 PRP injection;Standard care Hyaluronic acid eye drops
29 Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood Unknown status NCT02153515 Phase 3
30 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
31 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3 Tocilizumab;Placebo
32 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
33 Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation Unknown status NCT01174329 Phase 2, Phase 3
34 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
35 Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Completed NCT02610868 Phase 3 MYOBLOC
36 Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases Completed NCT02425176 Phase 2, Phase 3 Botulinum toxin A (BoNT-A) 50U;Botulinum toxin A (BoNT-A) 100U;Botulinum toxin A (BoNT-A) 200U
37 Metoclopramide as Treatment of Clozapine-induced Hypersalivation Completed NCT02222220 Phase 3 Metoclopramide;placebo
38 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
39 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity Completed NCT01652001 Phase 2, Phase 3 Malic Acid
40 Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation Completed NCT00534573 Phase 3 Amisulpride, Moclobemide
41 A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer Completed NCT02941276 Phase 3
42 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
43 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
44 Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas Completed NCT00158691 Phase 3 Ethyol
45 Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome Completed NCT03865888 Phase 3 Cyclosporins;Tacrolimus
46 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
47 A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503189 Phase 3 KCT-0809 ophthalmic solution;Placebo
48 A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503163 Phase 3 KCT-0809 ophthalmic solution
49 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
50 Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions Completed NCT02091739 Phase 3 IncobotulinumtoxinA (100 Units);IncobotulinumtoxinA (75 Units);Placebo

Search NIH Clinical Center for Salivary Gland Disease

Genetic Tests for Salivary Gland Disease

Anatomical Context for Salivary Gland Disease

MalaCards organs/tissues related to Salivary Gland Disease:

42
Salivary Gland, Eye, Lymph Node, Brain, Kidney, Ovary, Liver

Publications for Salivary Gland Disease

Articles related to Salivary Gland Disease:

(show top 50) (show all 100)
# Title Authors Year
1
Sialendoscopy in treating pediatric salivary gland disorders: a systematic review. ( 29204918 )
2018
2
Diagnostic work-up in obstructive and inflammatory salivary gland disorders. ( 28516970 )
2017
3
Biomarkers in Autoimmune Salivary Gland Disorders: A Review. ( 28231569 )
2017
4
Distinct BK polyomavirus non-coding control region (NCCR) variants in oral fluids of HIV- associated Salivary Gland Disease patients. ( 27085139 )
2016
5
Outcomes of interventional sialendoscopy for obstructive salivary gland disorders: an Italian multicentre study. ( 28177330 )
2016
6
HIV-associated salivary gland disease--clinical or imaging diagnosis? ( 25187268 )
2015
7
Oral mucocele/ranula: Another human immunodeficiency virus-related salivary gland disease? ( 25446909 )
2015
8
Effectiveness and costs of sialendoscopy in pediatric patients with salivary gland disorders. ( 26010768 )
2015
9
Salivary gland disease in Sjögren's syndrome: sialoadenitis to lymphoma. ( 24287195 )
2014
10
Focused review of investigation, management and outcomes of salivary gland disease in specialty-specific journals. ( 24792858 )
2014
11
Sialoendoscopy in the management of salivary gland disorders--4 years experience. ( 24834589 )
2014
12
Salivary gland disorders. ( 25077394 )
2014
13
Salivary gland disorders. ( 25443682 )
2014
14
The Role of Magnetic Resonance Imaging and Magnetic Resonance Sialography in the Diagnosis of Various Salivary Gland Disorders: An Interobserver Agreement. ( 31051982 )
2014
15
Is sialendoscopy an effective treatment for obstructive salivary gland disease? ( 23404254 )
2013
16
Natural killer cells regulate murine cytomegalovirus-induced sialadenitis and salivary gland disease. ( 22156514 )
2012
17
Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. ( 22710505 )
2012
18
Sialoendoscopy for the treatment of pediatric salivary gland disorders. ( 23069821 )
2012
19
Viruses and salivary gland disease (SGD): lessons from HIV SGD. ( 21441486 )
2011
20
Salivary gland disorders. ( 21094722 )
2011
21
Salivary gland disease. ( 20428015 )
2010
22
Diagnostic discussion. HIV-associated salivary gland disease (HIVSGD)-HIV related parotid cysts. ( 20443533 )
2010
23
HIV-associated salivary gland disease. ( 19608050 )
2009
24
Recent advances in the management of salivary gland disease. ( 19651463 )
2009
25
Clinical implications of the neck in salivary gland disease. ( 18603202 )
2008
26
A revolution in the management of obstructive salivary gland disease. ( 16512096 )
2006
27
Advances in the treatment of salivary gland disease. ( 17194041 )
2006
28
Salivary gland disease in pediatric HIV patients: an update. ( 15272653 )
2004
29
Clinical conditions and lesions mimicking salivary gland disease, part 1. ( 15622887 )
2004
30
Clinical conditions and lesions mimicking salivary gland disease: Part 2. ( 15633830 )
2004
31
Modern management of obstructive salivary gland disease. ( 16479855 )
2004
32
Diagnosis and treatment of salivary gland disorders. ( 15000634 )
2004
33
Salivary gland disease in HIV/AIDS and primary Sjögren's syndrome: analysis of collagen I distribution and histopathology in American and African patients. ( 12969229 )
2003
34
The genu of the submandibular duct--is the angle significant in salivary gland disease? ( 11803383 )
2002
35
Diagnosing, managing, and preventing salivary gland disorders. ( 11991308 )
2002
36
Comparative study of MR sialography and digital subtraction sialography for benign salivary gland disorders. ( 12372736 )
2002
37
Diagnosing salivary gland disease. ( 11462349 )
2001
38
Benign salivary gland disease. ( 11480124 )
2001
39
The role of MRI in facial swelling due to presumed salivary gland disease. ( 11718383 )
2001
40
Imaging of salivary gland disease. ( 10670049 )
2000
41
Salivary gland disease in human immunodeficiency virus-positive women from the WIHS study. Women's Interagency HIV Study. ( 10846124 )
2000
42
Salivary gland disorders. Neoplastic and nonneoplastic. ( 9927970 )
1999
43
The surgical management of salivary gland disease of the sublingual gland and floor of mouth. ( 11905350 )
1998
44
Bilateral and multicystic major salivary gland disease: a rare presentation of primary Sjögren's syndrome. ( 10209623 )
1998
45
Lupus erythematosus profundus around the salivary glands: a case resembling submandibular salivary gland disease. ( 9229369 )
1997
46
An association between salivary gland disease and serological abnormalities in Sjögren's syndrome. ( 9385581 )
1997
47
Salivary gland disorders and heredity. ( 9028463 )
1997
48
A guide to salivary gland disorders. ( 9061151 )
1997
49
Common salivary gland disorders: an update. ( 9879252 )
1997
50
Methods for the diagnosis of salivary gland disorders. ( 11507468 )
1997

Variations for Salivary Gland Disease

Expression for Salivary Gland Disease

Search GEO for disease gene expression data for Salivary Gland Disease.

Pathways for Salivary Gland Disease

Pathways related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
2 11.15 ERBB2 NFIB TP53
3 10.61 ERBB2 NTRK3 TP53

GO Terms for Salivary Gland Disease

Cellular components related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 ALKBH1 ALKBH3 CPSF4 CRTC1 CRTC3 ERBB2

Biological processes related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.72 ALKBH1 ETV6 ISL1 NTRK3 TP53
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.56 CRTC1 CRTC3 ETV6 ISL1 MAML2 NFIB
3 positive regulation of CREB transcription factor activity GO:0032793 9.4 CRTC1 CRTC3
4 neuron fate specification GO:0048665 9.37 ISL1 NTRK3
5 protein homotetramerization GO:0051289 9.33 CRTC1 CRTC3 TP53
6 DNA dealkylation involved in DNA repair GO:0006307 9.26 ALKBH1 ALKBH3
7 viral process GO:0016032 9.1 CPSF4 CRTC1 CRTC3 KRT7 SGTA TP53

Molecular functions related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.35 ETV6 ISL1 NFIB PLAG1 TP53
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 8.85 ALKBH1
3 cAMP response element binding protein binding GO:0008140 8.62 CRTC1 CRTC3

Sources for Salivary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....